My colleagues at FTI have a new white paper out surveying healthcare leaders on trends to anticipate in 2022. The data come from a survey of 251 senior decision makers employed in corporate
communications, investor relations, public affairs, business development, R&D and marketing for healthcare and life sciences companies in the U.S. Some key findings:
Drug pricing
More than two-thirds (69%) expect significant changes to our policy is going to be made on drug pricing under the Biden Administration over the next Twelve months.
Reputation
Diversity
Deal-making
Deal-making is predicted to rise in 2022. The most significant increase is anticipated in healthcare IPO activity, with 65% (+12% since 2022) planning on be higher in 2022,
and 1 in 4 (24%) planning on be “far higher.” Nearly 7 in 10 (65%) expect M&A activity to be higher in 2022, rising +5% from this past year, and majority (57%) also foresee higher SPAC
activity in 2022 compared to the previous Twelve months.
Hybrid vs. in-person workplace
When it comes to planning for a return to the workplace, 78% are optimistic that a
workable balance are available. Information mill, however, split within their approach, with
49% planning to offer a hybrid working approach, while 43% are considering returning to pre-pandemic working.
Source link
